补体3在乳腺癌中的表达差异及临床意义的生物信息学分析  

Bioinformatics analysis of differential expression and clinical significance of complement 3 in breast cancer

作　　者：张琴琴 王俊楠[3] 林厚民 伍莹 谭月梅 李明洲 金俊飞 王宁霞 洪勇[1] Zhang Qinqin;Wang Junnan;Lin Houmin;Wu Ying;Tan Yuemei;Li Mingzhou;Jin Junfei;Wang Ningxia;Hong Yong(Department of Thyroid and Breast Surgery,Nanxishan Hospital of Guangxi Zhuang Autonomous Region,Guilin 541002,China;Department of Breast Surgery,the First Affiliated Hospital of Jinan University,Guangzhou 510630,China;Guilin Medical University,Guilin 541000,China;Guangxi Laboratory Molecular Medicine in Liver Injury and Repair,Guilin 530008,China;Affiliated Hospital of Guilin Medical University,Guilin 541001,China)

机构地区：[1]广西壮族自治区南溪山医院甲状腺乳腺外科,桂林541002 [2]暨南大学附属第一医院乳腺外科,广州510630 [3]桂林医学院,桂林541000 [4]广西肝损伤与修复分子医学重点实验室,桂林530008 [5]桂林医学院附属医院,桂林541001

出　　处：《中华普通外科学文献（电子版）》2023年第4期271-277,共7页Chinese Archives of General Surgery(Electronic Edition)

基　　金：广西自然科学基金面上项目(2020GXNSFAA159051);广西肝脏损伤与修复分子医学重点实验室经费开放课题(GXLIRMMKL-201915);广西医疗卫生适宜技术开发与推广应用项目(S2020068);桂林市临床重点专科建设项目(市卫医〔2019〕36号);广西医疗卫生重点培育学科建设项目(桂卫医发〔2022〕17号)。

摘　　要：目的初步探究补体3(C3)在乳腺癌中的表达、预后评估价值、相关作用及潜在机制,为后期相关研究提供依据。方法使用TCGA、Breast Cancer Gene-Expression Miner、UALCAN、CPTAC、TIMER、Kaplan-Meier Plotter、GeneMANIA、DAVID等多个数据库对C3在泛癌中的表达、临床特征关系、预后价值、免疫相关性等进行综合分析,随后在乳腺癌中进行单基因差异分析,并进一步对C3在不同分型的乳腺癌做免疫细胞浸润相关性分析。结果TCGA数据库分析显示,C3在多种恶性肿瘤中的表达存在显著差异,并且与临床分期及预后相关;把表达差异、预后相关、临床分期相关取交集后发现C3在肾透明细胞癌、混合型肾癌、甲状腺癌、乳腺浸润癌、肝细胞癌5种肿瘤中呈现出表达差异,与预后及临床分期相关。C3在乳腺癌中为低表达;而癌组织中C3 mRNA水平与预后呈正相关,在非配对及配对分析中发现C3在乳腺癌组织中的表达均低于正常乳腺组织,其差异均具有统计学意义(P<0.001)。Survfit函数分析结果显示,C3低表达组和高表达组患者的总生存期(OS)预后差异有统计学意义(P=0.01),低C3表达水平与较短的OS相关。利用UALCAN平台分析C3 mRNA水平并绘制生存曲线,结果显示C3水平对乳腺癌有特异性诊断价值。TIMER数据库分析显示,C3在各种分型的乳腺癌中均与免疫细胞浸润呈正相关。结论C3在乳腺癌中低表达,有预后评估价值及特异性诊断价值,影响乳腺癌预后,机制可能与C3相关的免疫细胞浸润有关。补体通过肿瘤微环境对肿瘤免疫发挥重要作用。Objective To explore the expression,prognosis,function,underlying mechanisms and significance of complement 3(C3)in breast cancer,and to provide basis for further research on the mechanism of C3 in breast cancer.Methods TCGA,Breast Cancer Gene-Expression Miner,UALCAN,CPTAC,TIMER,Kaplan-Meier Plotter,GeneMANIA,DAVID were used for comprehensive analysis of the expression of C3 in the generic cancer,clinical features,prognostic value,and correlation immune.And then single genetic analysis was carried out by collecting clinical tissue samples for further validation Results TCGA database analysis showed that there were significant differences in the expression of C3 in various malignant tumors,and it was correlated with clinical stage and prognosis.After the intersection of expression difference,prognostic correlation and clinical stage correlation,it was found that C3 had significant differences in kidney renal clear cell carcinoma,pan-kidney cohort(KICH+KIRC+KIRP),thyroid carcinoma,breast invasive carcinoma,and hepatocellular carcinoma,which were related to prognosis and clinical stage.C3 was lowly expressed in breast cancer.The mRNA level of C3 in cancer tissues was positively correlated with the prognosis of breast cancer.The expression of C3 in breast cancer tissues was lower than that in normal breast tissues in both unpaired and paired analyses,and the differences were statistically significant(both P<0.001).The results of Survfit function showed that there was significantly prognostic difference in overall survival(OS)between patients with low and high C3 expression(P=0.01),and low C3 expression level was associated with shorter OS in cancers.The level of C3 mRNA was analyzed by UALCAN platform and the ROC curve was drawn.The results showed that C3 level had specific diagnostic value for breast cancer.TIMER database analysis showed that C3 was positively correlated with immune cell infiltration in all types of breast cancer.Conclusions C3 is lowly expressed in breast cancer,which has prognostic value and speci

关 键 词：补体3 乳腺肿瘤 肿瘤免疫 预后 生物计算学 

分 类 号：R737.9[医药卫生—肿瘤]